
## Antoinette O'Connor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9320256/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aβ profiles generated by Alzheimer's disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Molecular Psychiatry, 2022, 27, 2821-2832.	7.9	37
2	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	7.9	76
3	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. Brain, 2021, 144, 2176-2185.	7.6	66
4	Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. Brain, 2021, 144, 2964-2970.	7.6	16
5	Eye-tracking indices of impaired encoding of visual short-term memory in familial Alzheimer's disease. Scientific Reports, 2021, 11, 8696.	3.3	10
6	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	6.0	54
7	A novel presenilin 1 duplication mutation (Ile168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features. Neurobiology of Aging, 2021, 103, 137.e1-137.e5.	3.1	1
8	Visual short-term memory impairments in presymptomatic familial Alzheimer's disease: A longitudinal observational study. Neuropsychologia, 2021, 162, 108028.	1.6	7
9	Plasma pâ€ŧau231 in the Alzheimer's disease continuum: A multiâ€ɛohort evaluation of diagnostic performance, detection of Al² pathology and preclinical application. Alzheimer's and Dementia, 2021, 17, .	0.8	0
10	Accelerated longâ€ŧerm forgetting: Prognostic utility in familial Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
11	Disease duration in autosomal dominant familial Alzheimer disease. Neurology: Genetics, 2020, 6, e507.	1.9	13
12	Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimer's disease: a retrospective cohort analysis. Alzheimer's Research and Therapy, 2020, 12, 126.	6.2	13
13	Disease duration in autosomal dominant familial Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039738.	0.8	0
14	Plasma phosphoâ€ŧau in familial Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042921.	0.8	0
15	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
16	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2020, 16, 219-228.	0.8	13
17	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's diseaseâ€informed machineâ€learning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.8	47
18	O3â€03â€01: THE SEQUENCE AND TIMING OF PRECLINICAL COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P882.	0.8	1

#	Article	IF	CITATIONS
19	Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL–MRI: proof of concept. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2419-2432.	4.3	11
20	O2â€O4â€O4: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623.	0.8	0
21	P1â€524: VISUAL SHORTâ€TERM BINDING DEFICIT IN FAMILIAL ALZHEIMER'S DISEASE: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P532.	0.8	1
22	P3â€261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1174.	0.8	0